Dolutegravir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, Pharm.D., BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID
Dolutegravir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg

Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg

Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine

NON-FDA APPROVED USES

Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: September 13, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Dolutegravir ID - 540660 A1 - Pham,Paul,Pharm.D., BCPS AU - Smith,Janessa,Pharm.D. BCPS Y1 - 2018/09/13/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540660/all/Dolutegravir PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -